235 related articles for article (PubMed ID: 31981364)
1. Methotrexate treatment for patients with psoriasis and risk of cutaneous melanoma: a nested case-control study.
Polesie S; Gillstedt M; Paoli J; Osmancevic A
Br J Dermatol; 2020 Oct; 183(4):684-691. PubMed ID: 31981364
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate treatment and risk for cutaneous malignant melanoma: a retrospective comparative registry-based cohort study.
Polesie S; Gillstedt M; Sönnergren HH; Osmancevic A; Paoli J
Br J Dermatol; 2017 Jun; 176(6):1492-1499. PubMed ID: 27858996
[TBL] [Abstract][Full Text] [Related]
3. Use of methotrexate and risk of skin cancer: a nationwide case-control study.
Polesie S; Gillstedt M; Schmidt SAJ; Egeberg A; Pottegård A; Kristensen K
Br J Cancer; 2023 Mar; 128(7):1311-1319. PubMed ID: 36739322
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate Use for Patients with Psoriasis and Risk of Cutaneous Squamous Cell Carcinoma: A Nested Case-control Study.
Giannopoulos F; Gillstedt M; Laskowski M; Bruun Kristensen K; Polesie S
Acta Derm Venereol; 2021 Jan; 101(1):adv00365. PubMed ID: 33320276
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate Exposure and Risk of Cutaneous Malignant Melanoma: No Evidence of a Dose-response Relationship.
Polesie S; Gillstedt M; Paoli J; Osmancevic A
Acta Derm Venereol; 2018 Oct; 98(9):888-895. PubMed ID: 29972216
[TBL] [Abstract][Full Text] [Related]
6. Melanocytic nevi and risk of cutaneous malignant melanoma in southern Spain.
Ródenas JM; Delgado-Rodríguez M; Farinas-Alvarez C; Herranz MT; Serrano S
Am J Epidemiol; 1997 Jun; 145(11):1020-9. PubMed ID: 9169911
[TBL] [Abstract][Full Text] [Related]
7. Association Between Low-Dose Methotrexate Exposure and Melanoma: A Systematic Review and Meta-analysis.
Yan MK; Wang C; Wolfe R; Mar VJ; Wluka AE
JAMA Dermatol; 2022 Oct; 158(10):1157-1166. PubMed ID: 36044236
[TBL] [Abstract][Full Text] [Related]
8. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.
Busger Op Vollenbroek FTM; Doggen CJM; Janssens RWA; Bernelot Moens HJ
PLoS One; 2018; 13(3):e0194401. PubMed ID: 29570708
[TBL] [Abstract][Full Text] [Related]
9. Malignant melanoma: reduced risk associated with early childbearing and multiparity.
Lambe M; Thörn M; Sparén P; Bergström R; Adami HO
Melanoma Res; 1996 Apr; 6(2):147-53. PubMed ID: 8791273
[TBL] [Abstract][Full Text] [Related]
10. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study.
Chen YJ; Chang YT; Shen JL; Chen TT; Wang CB; Chen CM; Wu CY
Arthritis Rheum; 2012 Jun; 64(6):1879-87. PubMed ID: 22161801
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate did not add skin cancer risk in patients with psoriasis receiving narrowband ultraviolet B phototherapy: a nationwide retrospective cohort study.
Chao CH; Wu CY; Chou FL; Chen YJ
Clin Exp Dermatol; 2024 Apr; 49(5):459-465. PubMed ID: 38056487
[TBL] [Abstract][Full Text] [Related]
12. Do perinatal and early life exposures influence the risk of malignant melanoma? A Northern Ireland birth cohort analysis.
O'Rorke MA; Black C; Murray LJ; Cardwell CR; Gavin AT; Cantwell MM
Eur J Cancer; 2013 Mar; 49(5):1109-16. PubMed ID: 23146960
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.
Simberg-Danell C; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Carstensen J; Hansson J; Eriksson H
Int J Cancer; 2016 Aug; 139(3):543-53. PubMed ID: 27004457
[TBL] [Abstract][Full Text] [Related]
14. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.
Atallah E; Grove JI; Crooks C; Burden-Teh E; Abhishek A; Moreea S; Jordan KM; Ala A; Hutchinson D; Aspinall RJ; Murphy R; Aithal GP
J Hepatol; 2023 May; 78(5):989-997. PubMed ID: 36702175
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: an EORTC multicenter case-control study in Belgium, France and Germany. EORTC Melanoma Cooperative Group.
Autier P; Doré JF; Lejeune F; Koelmel KF; Geffeler O; Hille P; Cesarini JP; Lienard D; Liabeuf A; Joarlette M
Int J Cancer; 1994 Sep; 58(6):809-13. PubMed ID: 7927872
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
Prodanovich S; Ma F; Taylor JR; Pezon C; Fasihi T; Kirsner RS
J Am Acad Dermatol; 2005 Feb; 52(2):262-7. PubMed ID: 15692471
[TBL] [Abstract][Full Text] [Related]
17. Season of birth and other perinatal risk factors for melanoma.
Crump C; Sundquist K; Sieh W; Winkleby MA; Sundquist J
Int J Epidemiol; 2014 Jun; 43(3):793-801. PubMed ID: 24453238
[TBL] [Abstract][Full Text] [Related]
18. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous malignant melanoma in south Sweden 1965, 1975, and 1985. A histopathologic review.
Måsbäck A; Westerdahl J; Ingvar C; Olsson H; Jonsson N
Cancer; 1994 Mar; 73(6):1625-30. PubMed ID: 8156490
[TBL] [Abstract][Full Text] [Related]
20. Number of nevi at a specific anatomical site and its relation to cutaneous malignant melanoma.
Randi G; Naldi L; Gallus S; Di Landro A; La Vecchia C;
J Invest Dermatol; 2006 Sep; 126(9):2106-10. PubMed ID: 16645584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
